ReviewOxidative medicine and cellular longevity2016
The Janus-Faced Role of Antioxidants in Cancer Cachexia: New Insights on the Established Concepts.
Review in Oxidative medicine and cellular longevity, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 30 citations in OpenAlex.
- Phospholipid Glutathione Peroxidase Overexpression Mitigates Cancer Cachexia by Protecting Muscle Mass and Lowering Inflammation.Journal of cachexia, sarcopenia and muscle · 2026Article
- XOR-mediated tumor-selective nanomaterial therapy: achieving tumor and immune cell dual regulation through intracellular ROS generation.Journal of nanobiotechnology · 2026Article
- Targeting ROS in cancer: rationale and strategies.Nature reviews. Drug discovery · 2024Review
- Preventing loss of sirt1 lowers mitochondrial oxidative stress and preserves C2C12 myotube diameter in an in vitro model of cancer cachexia.Physiological reports · 2024Article
- Influence of Amino Acids and Exercise on Muscle Protein Turnover, Particularly in Cancer Cachexia.Cancers · 2024Review
- Low-Dose Non-Targeted Effects and Mitochondrial Control.International journal of molecular sciences · 2023Review
- Targeting Mitochondrial Metabolism to Reverse Radioresistance: An Alternative to Glucose Metabolism.Antioxidants (Basel, Switzerland) · 2022Review
- The double faced role of xanthine oxidoreductase in cancer.Acta pharmacologica Sinica · 2022Review
- Role for Plant-Derived Antioxidants in Attenuating Cancer Cachexia.Antioxidants (Basel, Switzerland) · 2022Review
- Review
- Exosomal microRNAs in cancer-related sarcopenia: Tumor-derived exosomal microRNAs in muscle atrophy.Experimental biology and medicine (Maywood, N.J.) · 2021Review
- Review
- Plant Extracts as Possible Agents for Sequela of Cancer Therapies and Cachexia.Antioxidants (Basel, Switzerland) · 2020Review
- Exercise shapes redox signaling in cancer.Redox biology · 2020Review
- Immunological Endotyping of Chronic Critical Illness After Severe Sepsis.Frontiers in medicine · 2020Review
- Do COJournal of enzyme inhibition and medicinal chemistry · 2019Article
- Moderate Exercise Improves Experimental Cancer Cachexia by Modulating the Redox Homeostasis.Cancers · 2019Article
- Doxorubicin triggers splenic contraction and irreversible dysregulation of COX and LOX that alters the inflammation-resolution program in the myocardium.American journal of physiology. Heart and circulatory physiology · 2018Article
- Group I Paks support muscle regeneration and counteract cancer-associated muscle atrophy.Journal of cachexia, sarcopenia and muscle · 2018Article
- Nutritional status and muscle dysfunction in chronic respiratory diseases: stable phase versus acute exacerbations.Journal of thoracic disease · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic inflammation and excessive loss of skeletal muscle usually occur during cancer cachexia, leading to functional impairment and delaying the cure of cancer. The release of cytokines by tumor promotes the formation of reactive oxygen species (ROS), which in turn regulate catabolic pathways involved in muscle atrophy. ROS also exert a dual role within tumor itself, as they can either promote proliferation and vascularization or induce senescence and apoptosis. Accordingly, previous studies that used antioxidants to modulate these ROS-dependent mechanisms, in cancer and cancer cachexia, have obtained contradictory results, hence the need to gather the main findings of these studies and draw global conclusions in order to stimulate more oriented research in this field. Based on the literature reviewed in this paper, it appears that antioxidant supplementation is (1) beneficial in cancer cachectic patients with antioxidant deficiencies, (2) most likely harmful in cancer patients with adequate antioxidant status (i.e., lung, gastrointestinal, head and neck, and esophageal), and (3) not recommended when undergoing radiotherapy. At the moment, measuring the blood levels of antioxidants may help to identify patients with systemic deficiencies. This approach is simple to realize but could not be a gold standard method for cachexia, as it does not necessarily reflect the redox state in other organs, like muscle.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.